Current Status and Future Development of Boron Neutron Capture Therapy
10.3971/j.issn.1000-8578.2026.25.0967
- VernacularTitle:硼中子俘获治疗现状及发展方向
- Author:
Jia MA
1
;
Yuli BAI
1
;
Guang HAN
1
Author Information
1. Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Boron neutron capture therapy;
Clinical treatment status;
Research development
- From:
Cancer Research on Prevention and Treatment
2026;53(4):243-250
- CountryChina
- Language:Chinese
-
Abstract:
Boron neutron capture therapy (BNCT) is a precision radiotherapy technology for tumors. On the international stage, Japan stands out as a representative country where BNCT has progressed into a mature clinical phase. Although China started relatively late, it has achieved rapid advancements through independent research and development in accelerator and neutron source equipment, domestically produced boron drugs, and clinically validated therapeutic efficacy. In several key indicators, China has now reached internationally advanced levels. Looking ahead, efforts should be prioritized toward the development of third-generation boron-based drugs, the standardization of treatment protocols, and cost reduction to enhance treatment accessibility, ultimately aiming to build a competitive BNCT clinical application and technological innovation system.
